Acute Respiratory Distress Syndrome - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H1 2015', provides an overview of the Acute Respiratory Distress Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Respiratory Distress Syndrome Overview 9 Therapeutics Development 10 Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10 Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11 Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12 Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 13 Acute Respiratory Distress Syndrome - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Acute Respiratory Distress Syndrome - Products under Development by Companies 16 Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 18 Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 19 Altor BioScience Corporation 19 BioMarck Pharmaceuticals, Ltd. 20 Faron Pharmaceuticals Oy 21 FirstString Research, Inc. 22 GlaxoSmithKline plc 23 Histocell S.L. 24 Mallinckrodt plc 25 Myelo Therapeutics GmbH 26 Navigen Pharmaceuticals, Inc. 27 Phylogica Limited 28 Serendex Pharmaceuticals A/S 29 Therabron Therapeutics, Inc. 30 Therametrics holding AG 31 Acute Respiratory Distress Syndrome - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 ALT-836 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 BIO-10901 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CG-367 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 corticotropin - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DasKloster-0141-01 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 DasKloster-1000-04 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 dilmapimod - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 GSK-2586881 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 GSK-2862277 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 interferon beta-1a - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 molgramostim - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Monoclonal Antibody to Inhibit E-selectin for Acute Respiratory Distress Syndrome - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Myelo-001 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 perfluorocarbon - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 PYC-35 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 PYC-36 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 PYC-38 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PYC-98 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 S-1229 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Slit2N - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Acute Respiratory Distress Syndrome - Recent Pipeline Updates 73 Acute Respiratory Distress Syndrome - Dormant Projects 77 Acute Respiratory Distress Syndrome - Discontinued Products 79 Acute Respiratory Distress Syndrome - Product Development Milestones 80 Featured News & Press Releases 80 Dec 20, 2013: Faron receives scientific advise from the EMA on the FP-1201-lyo clinical development 80 Oct 22, 2013: Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome 80 Nov 29, 2012: Faron Pharma Receives €6m Grant From European Commission For Traumakine Program 81 May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 81 Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 82 May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 82 Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201 83 Jan 17, 2011: Rentschler And Faron Pharma Sign Manufacturing And Supply Agreement For Traumakine 83 Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study 84 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 85 Disclaimer 86
List of Tables Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2015 10 Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Development by Companies, H1 2015 (Contd..1) 17 Products under Investigation by Universities/Institutes, H1 2015 18 Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H1 2015 19 Acute Respiratory Distress Syndrome - Pipeline by BioMarck Pharmaceuticals, Ltd., H1 2015 20 Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2015 21 Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H1 2015 22 Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline plc, H1 2015 23 Acute Respiratory Distress Syndrome - Pipeline by Histocell S.L., H1 2015 24 Acute Respiratory Distress Syndrome - Pipeline by Mallinckrodt plc, H1 2015 25 Acute Respiratory Distress Syndrome - Pipeline by Myelo Therapeutics GmbH, H1 2015 26 Acute Respiratory Distress Syndrome - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 27 Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H1 2015 28 Acute Respiratory Distress Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 29 Acute Respiratory Distress Syndrome - Pipeline by Therabron Therapeutics, Inc., H1 2015 30 Acute Respiratory Distress Syndrome - Pipeline by Therametrics holding AG, H1 2015 31 Assessment by Monotherapy Products, H1 2015 32 Number of Products by Stage and Target, H1 2015 34 Number of Products by Stage and Mechanism of Action, H1 2015 36 Number of Products by Stage and Route of Administration, H1 2015 38 Number of Products by Stage and Molecule Type, H1 2015 40 Acute Respiratory Distress Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 73 Acute Respiratory Distress Syndrome - Dormant Projects, H1 2015 77 Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H1 2015 78 Acute Respiratory Distress Syndrome - Discontinued Products, H1 2015 79
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.